Research programme: cell-based anticancer therapeutic - IDMAlternative Names: Ex vivo cancer therapeutic research programme - IDM
Latest Information Update: 15 Feb 2008
$50 / €47 *
At a glance
- Originator IDM S.A.
- Developer IDM S.A.; NEMOD Biotherapeutics [CEASED]
- Class Cell therapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Apr 2005 Suspended - Preclinical for Cancer in France (Parenteral)
- 08 Apr 2005 Suspended - Preclinical for Cancer in Germany (Parenteral)
- 21 Oct 2002 Preclinical trials in Cancer in France (Parenteral)